SCHEMBL4715575

SCHEMBL4715575

COc1ccccc1C=Cc1cccc(C)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.62
RAB9A P51151 5/20 0.62
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
DHFR P00374 1/20 0.57
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 3/20 0.56
GRM5 P41594 1/20 0.56
GRM4 Q14833 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
PKM P14618 1/20 0.56
HPGD P15428 1/20 0.56
TSHR P16473 1/20 0.56
NFKB1 P19838 1/20 0.56
CYP2C19 P33261 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715571 1.00 NPC1 (0.62) NPC1RAB9AMEN1KMT2ADHFR
SCHEMBL4713137 0.88 NPC1 (0.64) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL4713133 0.88 NPC1 (0.64) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL4713357 0.86 NPC1 (0.68) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL4713361 0.86 NPC1 (0.68) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL11631167 0.81 NPC1 (0.49) NPC1RAB9AMEN1KMT2ADHFR
SCHEMBL4715307 0.81 MEN1 (0.52) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL4715311 0.81 MEN1 (0.52) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL11631170 0.81 NPC1 (0.49) NPC1RAB9AMEN1KMT2ADHFR
SCHEMBL27403426 0.81 NPC1 (0.55) NPC1RAB9AMEN1KMT2ADHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed